News | June 08, 2026
Roche signs up to $2.3 billion deal with Nurix for BTK degrader Bexobrutideg
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
Targeting deadly drug-resistant acinetobacter infections
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
BMS is moving beyond conversational AI into what it describes as “agentic” systems
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
